Exacis Biotherapeutics Included on Inside Precision Medicine’s Five RNA Therapeutics Startups to Watch in 2022 List
Five RNA Therapeutics Startups to Watch in 2022
Advanced Therapies Conference to Include Gene Modified Therapy Track – Exacis Biotherapeutics CEO to Participate in Panel Discussion
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will serve on a panel exploring the difference between autologous and allogeneic stem cell therapies during the Advanced Therapies Conference.
Cancer Progress Conference to Present Cost-Benefit Considerations for Complex Therapeutics- Panelists Include Exacis Biotherapeutics CEO
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will discuss strategies for optimal positioning of new therapies as a panel member at the Cancer Progress Conference.
Exacis Biotherapeutics CEO to Serve on Expert Panel at Longwood Healthcare Leaders Meeting
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will join of an expert panel of biotherapeutic leaders to discuss “Aligning Priorities with the Board” during the Longwood Healthcare Leaders Meeting.
Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of iPSC-Derived mRNA-Engineered NK Cells
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis' innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer. The partnership also includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM, which will be used to fund operations.
CAR T Cells: Off the Shelf and On the Mark
After notching a handful of regulatory approvals in the last four years, chimeric antigen receptor (CAR) T-cell therapies are beginning to deliver remarkable efficacy for cancer patients—albeit with some concrete limitations.
Exacis Biotherapeutics Announces Key Additions To Company’s Scientific Advisory Board
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced the addition of three oncology and cell therapy experts to its Scientific Advisory Board (SAB): Pamela Munster, MD; Caron Jacobson, MD, MMSc; and Evren Alici, MD, PhD.
Exacis Biotherapeutics Makes Strategic Investment In Manufacturing By Hiring Head Of Technical Operations and Securing Space In A GMP Cleanroom Facility Recently Completed By Factor Bioscience
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer
Exacis Biotherapeutics Presents Data On Its Stealth mRNA-engineered NK-cell Platform At American Society Of Gene & Cell Therapy Annual Meeting
Exacis produces its iPSC-derived ExaNK™ cells using its proprietary mRNA-based cell reprogramming and gene editing technologies
Exacis Biotherapeutics Develops mRNA-Engineered iPSC-Derived NK Cells For Difficult-To-Treat Tumors
Exacis has generated NK cells from iPSCs engineered using mRNA gene-editing technology to resist rejection by the patient’s immune system.